BidaskClub cut shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a strong sell rating in a report published on Friday.
Separately, Zacks Investment Research upgraded Achillion Pharmaceuticals from a sell rating to a hold rating in a research report on Thursday, June 28th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating and one has issued a buy rating to the company. Achillion Pharmaceuticals has an average rating of Hold and a consensus target price of $4.38.
ACHN stock traded up $0.05 during trading on Friday, hitting $3.13. 952,353 shares of the company traded hands, compared to its average volume of 1,459,196. The stock has a market cap of $510.00 million, a P/E ratio of -5.05 and a beta of 1.27. Achillion Pharmaceuticals has a 1 year low of $2.33 and a 1 year high of $4.63.
Several institutional investors have recently bought and sold shares of the company. Northern Trust Corp increased its position in shares of Achillion Pharmaceuticals by 1.9% in the second quarter. Northern Trust Corp now owns 1,604,822 shares of the biopharmaceutical company’s stock valued at $4,541,000 after buying an additional 30,669 shares in the last quarter. Cubist Systematic Strategies LLC purchased a new stake in shares of Achillion Pharmaceuticals in the second quarter valued at approximately $147,000. Bank of America Corp DE increased its position in shares of Achillion Pharmaceuticals by 14.5% in the second quarter. Bank of America Corp DE now owns 416,817 shares of the biopharmaceutical company’s stock valued at $1,179,000 after buying an additional 52,634 shares in the last quarter. RTW Investments LP increased its position in shares of Achillion Pharmaceuticals by 0.3% during the second quarter. RTW Investments LP now owns 13,541,997 shares of the biopharmaceutical company’s stock worth $38,324,000 after purchasing an additional 45,095 shares in the last quarter. Finally, BlueMountain Capital Management LLC purchased a new stake in shares of Achillion Pharmaceuticals during the second quarter worth approximately $159,000. Institutional investors and hedge funds own 78.36% of the company’s stock.
Achillion Pharmaceuticals Company Profile
Achillion Pharmaceuticals, Inc, a biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders in the United States. Its lead drug candidate includes ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria and C3 glomerulopathy.
Featured Article: Price to Earnings Ratio (PE) Basics
Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.